000307637 001__ 307637
000307637 005__ 20260115152944.0
000307637 0247_ $$2doi$$a10.1007/s00259-025-07712-2
000307637 0247_ $$2pmid$$apmid:41528461
000307637 0247_ $$2ISSN$$a1619-7070
000307637 0247_ $$2ISSN$$a1619-7089
000307637 037__ $$aDKFZ-2026-00108
000307637 041__ $$aEnglish
000307637 082__ $$a610
000307637 1001_ $$aSpäth, Magdalena Sophie$$b0
000307637 245__ $$aPET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT).
000307637 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2026
000307637 3367_ $$2DRIVER$$aarticle
000307637 3367_ $$2DataCite$$aOutput Types/Journal article
000307637 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768487360_984431
000307637 3367_ $$2BibTeX$$aARTICLE
000307637 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307637 3367_ $$00$$2EndNote$$aJournal Article
000307637 500__ $$a#DKTKZFB26# / epub
000307637 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000307637 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307637 650_7 $$2Other$$aPET
000307637 650_7 $$2Other$$aProstate cancer
000307637 650_7 $$2Other$$aRadiopharmaceutical therapy
000307637 650_7 $$2Other$$aVisceral metastases
000307637 650_7 $$2Other$$a[177Lu]PSMA
000307637 7001_ $$aDittmann, Helmut$$b1
000307637 7001_ $$aSpallek, Richard$$b2
000307637 7001_ $$aCalderón, Eduardo$$b3
000307637 7001_ $$aMück, Jonas$$b4
000307637 7001_ $$aBrendlin, Andreas$$b5
000307637 7001_ $$aRausch, Steffen$$b6
000307637 7001_ $$0P:(DE-HGF)0$$ala Fougère, Christian$$b7
000307637 7001_ $$00000-0003-3397-6299$$aTrautwein, Nils F$$b8
000307637 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07712-2$$pnn$$tEuropean journal of nuclear medicine and molecular imaging$$vnn$$x1619-7070$$y2026
000307637 909CO $$ooai:inrepo02.dkfz.de:307637$$pVDB
000307637 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000307637 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000307637 9141_ $$y2026
000307637 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000307637 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000307637 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000307637 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000307637 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK Koordinierungsstelle Tübingen$$x0
000307637 980__ $$ajournal
000307637 980__ $$aVDB
000307637 980__ $$aI:(DE-He78)TU01-20160331
000307637 980__ $$aUNRESTRICTED